



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RESPONSES TO SGX REGCO'S QUERIES RECEIVED ON 18 SEPTEMBER 2025

The Board of Directors (the “**Board**” or “**Directors**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the Company's announcement dated 17 September 2025 in relation to the resignation of Chief Financial Officer.

The Company's responses to the queries received from the Singapore Exchange Regulation (“**SGX RegCo**”) on 18 September 2025 are set out below.

Query 1: We refer to the following “Mr Poh Khee Pow (“Mr Poh”) tendered his resignation as the Chief Financial Officer (“CFO”) of the Company on 26 May 2025 due to personal commitments and geographical constraints that require his physical presence in another country.”

Please explain why the Company did not make any immediate announcement on his resignation, noting that Mr Poh had tendered his resignation on 26 May 2025.

Company's response

Mr Poh Khee Pow tendered his resignation as Chief Financial Officer on 26 May 2025. At the point of tender, Mr Poh indicated his willingness to support a managed transition to safeguard ongoing finance, reporting and compliance deliverables while the Board considered succession arrangements. Over the following months, the Board and Mr Poh discussed the duration and scope of handover, including Mr Poh's effective cessation date, and the Board formally accepted Mr Poh's resignation. It was only after which the Board and Mr Poh came to an mutually agreed the effective cessation date in September 2025, and the Company accordingly made the timely announcement of the cessation on 17 September 2025.

The Company's understanding at the material time was that market disclosure should be made when the effective cessation date was confirmed, so that the announcement would be accurate and complete.

Query 2: Please address whether and how the Company has complied with Catalist Rule 704(6), and if no, why not. Please provide the assessment and basis of both the Board and the Sponsor in your response.

Company's and Sponsor's response

The Company made its announcement upon the Board's confirmation of the effective cessation date on 17 September 2025. On this basis, the Company has complied with Catalist Rule 704(6).

The Board and Sponsor are of the view that the Company had acted in good faith to ensure clarity and operational continuity. An immediate announcement upon receipt of the notice of resignation, but without clarity on the cessation date would have rendered the announcement incomplete with insufficient information for investors to evaluate the relative importance of the announcement, as guided by Practice Note 7A of the Catalist Rules.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
19 September 2025

Singapore Institute of Advanced Medicine Holdings Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("SGX-ST") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.